Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocCheck AGFRA:AJ91 71 Debt-to-EBITDA is 0.34 as of Dec. 2025, which is 6% below its 10-year median of 0.36. GuruFocus rates FRA:AJ91 with a GF Score™ of 71/100 and a GF Value™ of €9.41 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 478 Healthcare Providers & Services companies, DocCheck AG ranks better than 84.1% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for DocCheck AG's Debt-to-EBITDA or its related term are showing as below:
FRA:AJ91'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.36 Max: 0.61
Current: 0.36
During the past 13 years, the highest Debt-to-EBITDA Ratio of DocCheck AG was 0.61. The lowest was 0.01. And the median was 0.36.
FRA:AJ91's Debt-to-EBITDA is ranked better than 84.1% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs FRA:AJ91: 0.36
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
DocCheck AG Debt-to-EBITDA Related Terms
DocCheck AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for DocCheck AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AJ91 vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, DocCheck AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocCheck AG Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DocCheck AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
DocCheck AG (FRA:AJ91) has a Debt-to-EBITDA of 0.34 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DocCheck AG. This is near median its historical median of 0.36. Over the past decade, DocCheck AG's Debt-to-EBITDA has ranged from 0.01 to 0.61. According to the industry distribution chart, DocCheck AG ranks #76 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 15.9%.
Is DocCheck AG's Debt-to-EBITDA too high?
DocCheck AG's current Debt-to-EBITDA of 0.34 is near median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.61. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. DocCheck AG's value of 0.34 is 84.4% below this industry median. Based on the distribution chart, DocCheck AG ranks #76 out of 478 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DocCheck AG has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DocCheck AG's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DocCheck AG ranks #76 out of 478 companies for Debt-to-EBITDA. This places DocCheck AG in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.19. DocCheck AG's value of 0.34 is 84.4% below this benchmark. Historically, DocCheck AG's own Debt-to-EBITDA has ranged from 0.01 to 0.61 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 2.19, DocCheck AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocCheck AG's current Debt-to-EBITDA of 0.34 is 84.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DocCheck AG. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocCheck AG's current Debt-to-EBITDA is 0.34, which is near median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocCheck AG stock overvalued right now?
Based on GuruFocus' analysis, DocCheck AG (FRA:AJ91) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.41, compared to a current price of €10.90 — trading 15.8% above its estimated fair value. The current Debt-to-EBITDA is 0.34, which is near median its 10-year median of 0.36 and 84.4% below the Healthcare Providers & Services industry median of 2.19. DocCheck AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For DocCheck AG (FRA:AJ91), the current Debt-to-EBITDA is 0.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocCheck AG (FRA:AJ91) Overvalued in 2026?
Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued.
The current stock price of €10.90 is trading 15.8% above its estimated GF Value™ of €9.41.
GuruFocus considers DocCheck AG to be Modestly Overvalued.
Key valuation signals for FRA:AJ91:
Debt-to-EBITDA: 0.34 (near median its 10-year median of 0.36)
GF Value™: €9.41 vs. price of €10.90 (15.8% above fair value)
Industry Position: 84.4% below the Healthcare Providers & Services median (#76 of 478)
No single metric tells the full story. See the FRA:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
71GF Score
Get the complete analysis for FRA:AJ91
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AJ91 has been successfully added to your 
